Australia thrashes out patient access deals for Soliris/Kalydeco

The Australian authorities are to start funding the use of Alexion's Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) and Vertex' Kalydeco (ivacaftor) for cystic fibrosis under the Pharmaceutical Benefits Scheme (PBS) from 1 December.